Cantor Fitzgerald Reiterates “$55.00” Price Target for Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (NASDAQ:TBPH) has been given a $55.00 price target by stock analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 105.92% from the stock’s previous close.
A number of other research firms also recently commented on TBPH. ValuEngine raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a research report on Wednesday, August 2nd. Leerink Swann set a $47.00 target price on shares of Theravance Biopharma and gave the company a “buy” rating in a research report on Wednesday, May 10th. Finally, BidaskClub downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $41.13.
Shares of Theravance Biopharma (NASDAQ:TBPH) traded down 0.04% during midday trading on Wednesday, hitting $26.70. 57,908 shares of the stock were exchanged. The stock’s market cap is $1.44 billion. Theravance Biopharma has a 12 month low of $23.15 and a 12 month high of $43.44. The firm has a 50 day moving average of $34.99 and a 200-day moving average of $35.48.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/cantor-fitzgerald-reiterates-55-00-price-target-for-theravance-biopharma-inc-tbph/1495492.html.
In related news, Director Henrietta Fore bought 6,000 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average cost of $23.99 per share, for a total transaction of $143,940.00. Following the purchase, the director now directly owns 24,000 shares of the company’s stock, valued at $575,760. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Rick E. Winningham bought 10,000 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average price of $24.50 per share, with a total value of $245,000.00. Following the completion of the purchase, the chief executive officer now directly owns 866,377 shares in the company, valued at $21,226,236.50. The disclosure for this purchase can be found here. 6.10% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the company. Teachers Advisors LLC boosted its stake in Theravance Biopharma by 19.2% in the fourth quarter. Teachers Advisors LLC now owns 69,563 shares of the biopharmaceutical company’s stock worth $2,218,000 after buying an additional 11,201 shares during the period. Wells Fargo & Company MN boosted its stake in Theravance Biopharma by 10.6% in the first quarter. Wells Fargo & Company MN now owns 32,270 shares of the biopharmaceutical company’s stock worth $1,188,000 after buying an additional 3,100 shares during the period. American Century Companies Inc. bought a new stake in Theravance Biopharma during the first quarter worth approximately $1,132,000. Bank of New York Mellon Corp boosted its stake in Theravance Biopharma by 2.6% in the first quarter. Bank of New York Mellon Corp now owns 206,023 shares of the biopharmaceutical company’s stock worth $7,586,000 after buying an additional 5,188 shares during the period. Finally, Swiss National Bank boosted its stake in Theravance Biopharma by 1.7% in the first quarter. Swiss National Bank now owns 64,442 shares of the biopharmaceutical company’s stock worth $2,373,000 after buying an additional 1,100 shares during the period. Institutional investors own 82.77% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.